Bogdan Żurawski

9.1k citations

37 papers · 773 indexed · 2 hit papers · h-index 15

Oncology top 5%
- Cancer Immunotherapy and Biomarkers 15
- Lung Cancer Research Studies 7
Pulmonary and Respiratory Medicine top 5%
- Lung Cancer Treatments and Mutations 12
- Prostate Cancer Treatment and Research 5
- Brain Metastases and Treatment 4
Cancer Research
- Cancer Genomics and Diagnostics 5
Genetics
- Glioma Diagnosis and Treatment 4
Immunology
Radiology, Nuclear Medicine and Imaging
- Radiopharmaceutical Chemistry and Applications 5

Co-authors: Paweł Izdebski Monika Wiłkość-Dębczyńska Marzena Anna Lewandowska Luis Paz‐Ares Martin Reck Michael Schenker Wojciech Jóźwicki Mauricio Burotto
Cited by: Oncology Pulmonary and Respiratory Medicine Cancer Research
Journals: Annals of Oncology (11 papers)Journal of Clinical Oncology (8 papers)Journal of Thoracic Oncology (3 papers)
Partner nations: United States Poland Spain

In The Last Decade

Bogdan Żurawski

37 papers receiving 764 citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Bogdan Żurawski

Since Specialization

Citations

This map shows the geographic impact of Bogdan Żurawski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bogdan Żurawski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bogdan Żurawski more than expected).

Fields of papers citing papers by Bogdan Żurawski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bogdan Żurawski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bogdan Żurawski. The network helps show where Bogdan Żurawski may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Bogdan Żurawski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bogdan Żurawski Line = papers co-authored together Bogdan Żurawski links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	291O DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC) Annals of Oncology ·А.В. Поротов,はるみ大倉,睦奥山,Shinji Ohno,Alba Briones Martín,S.B. Kim,أحمودة محمد البشير,Xuchen Cao,Verônica Cristina Gomes Soares,Rong Li,Bogdan Żurawski,Santiago Escrivá-de-Romaní,Don C. Quast,أحمد أحمد علي الآنسي,G. Curigliano,Yannis Benzoubair,S. Mondal,正志澤田,Norbert Wittmann,Eamon Hamilton	2025	1
2	CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology ·Neeraj Agarwal,Arun Azad,Joan Carles,Nobuaki Matsubara,Stéphane Oudard,Fred Saad,Axel S. Merseburger,Andrey Soares,Bradley A. McGregor,Bogdan Żurawski,Scott North,Marinos Tsiatas,Igor Bondarenko,Niina Khan,Marc Perronin,Keerti Vardhan Sharma,M. Ramjeet,Roberta Ferraldeschi,Fong Wang,Sumanta K. Pal	2024	20
3	LBA67 Cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final overall survival (OS) results of the phase III, randomized, CONTACT-02 study Annals of Oncology ·Neeraj Agarwal,Arun Azad,(unknown),Ram Bhattarai,Stéphane Oudard,Fred Saad,Axel S. Merseburger,Andrey Soares,Bradley A. McGregor,Bogdan Żurawski,Marinos Tsiatas,Scott North,Evangelos Bournakis,Mohamed R. Khalil,Djedjiga Abdelli,Marc Perronin,Andrew D. Simmons,Roberta Ferraldeschi,M. Ramjeet,K. Wacker	2024	4
4	64O Lenvatinib plus pembrolizumab, pemetrexed, and a platinum (len + pembro + chemo) as first-line therapy for metastatic non squamous non-small cell lung cancer (NSCLC): Phase III LEAP-006 study Immuno-Oncology Technology ·Roy S. Herbst,Byoung Chul Cho,Caicun Zhou,Mauricio Burotto,Manuel Cobo,Mehmet Alı Nahıt Şendur,Vladimir Moiseyenko,Bogdan Żurawski,Ignacio Casarini,Makoto Nishio,Rina Hui,Elvire Pons‐Tostivint,Julia Dudnik,Wei Zhang,Chinyere E. Okpara,Lei Yin,Yun Luo,Niyati Bhagwati,Delvys Rodríguez‐Abreu	2023	3
5	1806P Efficacy of niraparib and abiraterone acetate plus prednisone (NIRA+AAP) in homologous recombination repair gene-altered (HRR+) metastatic castration-resistant prostate cancer (mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial Annals of Oncology ·G. Attard,Shahneen Sandhu,Dana E. Rathkopf,Elena Castro,Marniza Saad,Mitchell R. Smith,Eric J. Small,David Olmos,S.V. FEDOSOV,Guilhem Roubaud,Bogdan Żurawski,Eleni Efstathiou,Daphne Wu,B. Diorio,Karen Urtishak,Umesh Singh,Yan Xu,Angela Lopez‐Gitlitz,MT Gomez Sánchez,K.N. Chi	2023	2
6	Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry European Urology Open Science ·Anders Bjartell,Luís Costa,Gero Kramer,Bogdan Żurawski,Luca Galli,Patrick Werbrouck,Thorsten Ecke,Omi Parikh,Mostefa Bennamoun,H.S. Kim,Avivit Peer,Börje Ljungberg,İrfan Çiçin,Emma Smith,Martin Lukáč,Robert Wapenaar,Simon Chowdhury	2022	7
7	Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. Journal of Clinical Oncology ·Kim N.,Dana E. Rathkopf,Matthew R. Smith,Eleni Efstathiou,Gerhardt Attard,David Olmos,Ji Youl Lee,Eric J. Small,Andrea Juliana Gomes,Guilhem Roubaud,Marniza Saad,Bogdan Żurawski,V.S. Sakalo,Gary Mason,Adam del Corral,George Wang,Daphne Wu,Brooke Diorio,Amy Beth Sharron,Shahneen Sandhu	2022	81
8	OA03.03 Nivolumab (NIVO) + ipilimumab (IPI) Versus Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment for Advanced Non-Small Cell Lung Cancer (aNSCLC): 3-year Update from CheckMate 227 Part 1 Journal of Thoracic Oncology ·Subhankar Mazumdar,Tudor–Eliade Ciuleanu,Adam Płużański,J.-S. Lee,Michael Schenker,Beth Trask,SujithJ Chandy,Bogdan Żurawski,Clarisse Audigier-Valette,Mariano Provencio,Helena Linardou,Subramanian Sankar,Hossein Borghaei,Matthew D. Hellmann,Kenneth J. O’Byrne,Luis Paz‐Ares,Martin Reck,Faith E. Nathan,Julie R. Brahmer	2021	2
9	Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study ESMO Open ·Jonathan A. Ledermann,Bogdan Żurawski,Francesco Raspagliesi,Ugo De Giorgi,R Ostime Committee,Mar Marín,Alla Lisyanskaya,Ròbert Póka,Janina Markowska,C. Cebotaru,A. Casado Herráez,Nicoletta Colombo,E. Kutarska,Marcia Hall,Adam Jacobs,S Mazur,Harald Baumeister,Alfredo Zurlo,Jalid Sehouli	2021	14
10	67P Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1 Annals of Oncology ·Julie R. Brahmer,T-E. Ciuleanu,Michael Schenker,Clarisse Audigier-Valette,Bogdan Żurawski,Helena Linardou,S-W. Kim,Andrés Huérfano Celis,Pamela Salman,Emmanuel de la Mora Jimenez,Krzysztof Leśniewski-Kmak,Yrd. Doç. Dr. Hande ŞAHİN,István Albert,Fabrice Barlési,Kynan Feeney,Norbert Frickhofen,A. Li,Ping‐Hui Sun,Matthew D. Hellmann	2020	3
11	LBA59 First-line nivolumab (NIVO) + ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA Annals of Oncology ·Martin Reck,T-E. Ciuleanu,Manuel Cobo,Michael Schenker,Bogdan Żurawski,J. Menezes,Eduardo Richardet,Jaafar Bennouna,Ying Cheng,Luis Paz‐Ares,Sheng-Feng Lu,Thomas John,JORDAN SCOTT,Xiaowu Sun,Iartsev Vn,H. S. Green,Yong Yuan,Steven I. Blum,David P. Carbone	2020	5
12	696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial Annals of Oncology ·Toni K. Choueiri,Thomas Powles,Mauricio Burotto,María T. Bourlon,Bogdan Żurawski,Víctor Manuel Oyervides-Juárez,James J. Hsieh,Umberto Basso,Amishi Y. Shah,Cristina Suárez,小林祥之,Carlos H. Barrios,Martin Eduardo Richardet,David Pook,Yoshihiko Tomita,Bernard Escudier,Simon Dürr,Burçin Şimşek,Andrea B. Apolo,Robert J. Motzer	2020	85
13	Detection of somatic mutations in ctDNA derived from adenocarcinoma patients – EGFR tyrosine kinase inhibitor monitoring preliminary study Współczesna Onkologia ·Marzena Anna Lewandowska,Roscoe Ah,Henry Giovanni Pinilla,Yin Ya-lin,Bogdan Żurawski,مالا نانسی,Manuela Las‐Jankowska,Krzysztof Roszkowski,Janusz Kowalewski	2019	1
14	Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): Results from the randomized phase II RESGEX study. Journal of Clinical Oncology ·Ulrich Keilholz,Andrzej Kawecki,Andreas Dietz,Bogdan Żurawski,Michael Schenker,Bożena Kukiełka-Budny,Philippe Schafhausen,Sherif El-Eskandarany,Sebastián Ochenduszko,Ilaria Imarisio,偉彥黃,Cristina Oprean,Gunnar Folprecht,Xi Bin Wang,Sylvie Rottey,P. Debourdeau,Javier Lavernia,Bruno Dietrich,Alfredo Zurlo,Jérôme Fayette	2018	4
15	A double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma Annals of Oncology ·JA Ledermann,Jalid Sehouli,Bogdan Żurawski,Francesco Raspagliesi,Ugo De Giorgi,Susana Banerjee,R Ostime Committee,Mar Marín,Alla Lisyanskaya,Ròbert Póka,偉彥黃,Janina Markowska,C. Cebotaru,A. Casado Herráez,Nicoletta Colombo,Н. В. Коваленко,E. Kutarska,Marcia Hall,Riccardo Belli,Alfredo Zurlo	2017	13
16	A systemic literature review of neuroimaging studies in women with breast cancer treated with adjuvant chemotherapy Współczesna Onkologia ·Kommentar Zum Aktiengesetz,Monika Wiłkość-Dębczyńska,Paweł Izdebski,Bogdan Żurawski	2017	27
17	Use of lipegfilgrastim in clinical practice for the prophylaxis of chemotherapy-induced neutropenia: interim results of pan-European non-interventional study Annals of Oncology ·庄一中西,Nerée Claes,Patrizio Mazza,Bogdan Żurawski,猪熊健太郎,Edgar Petru,Е. С. Лихарева,藤本透子,Francesco Lanza,Christel Fontaine	2016	2
18	Verbal fluency in breast cancer patients treated with chemotherapy Breast Cancer ·Kommentar Zum Aktiengesetz,Monika Wiłkość-Dębczyńska,Bogdan Żurawski,Paweł Izdebski	2016	11
19	Impact of Specific KRAS Mutation in Exon 2 on Clinical Outcome of Chemotherapy- and Radiotherapy-Treated Colorectal Adenocarcinoma Patients Molecular Diagnosis & Therapy ·Krzysztof Roszkowski,Bogdan Żurawski,Wojciech Jóźwicki,Paweł Basta,Marzena Anna Lewandowska	2014	3
20	KRAS and BRAF Mutation Analysis in Colorectal Adenocarcinoma Specimens with a Low Percentage of Tumor Cells Molecular Diagnosis & Therapy ·Marzena Anna Lewandowska,Wojciech Jóźwicki,Bogdan Żurawski	2013	28

About Bogdan Żurawski

Bogdan Żurawski is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 37 papers that have together received 773 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (7 papers), Radiopharmaceutical Chemistry and Applications (5 papers), Cancer Genomics and Diagnostics (5 papers), Prostate Cancer Treatment and Research (5 papers), Glioma Diagnosis and Treatment (4 papers) and Brain Metastases and Treatment (4 papers). The work is most often cited by research in Oncology (528 citations), Pulmonary and Respiratory Medicine (534 citations) and Cancer Research (147 citations). Bogdan Żurawski has collaborated with scholars based in United States, Poland and Spain. Frequent co-authors include Paweł Izdebski, Monika Wiłkość-Dębczyńska, Marzena Anna Lewandowska, Luis Paz‐Ares, Martin Reck, Michael Schenker, Wojciech Jóźwicki, Mauricio Burotto, J. Menezes and Thomas Powles. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Journal of Thoracic Oncology, ESMO Open and Molecular Diagnosis & Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact